Phase III trial in 3307 patients with knee or hip osteoarthritis pain (1801 analysed for efficacy): fasinumab 1 mg Q4W reduced WOMAC pain and function more than placebo and naproxen at week 16, but arthropathies (9.7% vs 1.1% placebo) and joint replacements were higher.
RCTn = 3,307 patients
DiMartino et al. A phase III, randomised, double-blind, multi-dose, placebo- and naproxen-controlled study to evaluate the efficacy and safety of fasinumab in patients with pain due to osteoarthritis of the knee or hip